Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
F M LaForce

Abstract

The treatment of nosocomial pneumonia is difficult because of the absence of a precise microbial etiology in a sizable fraction of cases and the severity of predisposing conditions in patients who develop these infections. Staphylococcus aureus and aerobic gram-negative rods continue to be the most common isolates in these infections. Therapy of nosocomial pneumonia is often empiric, with initial antimicrobial therapy based upon local experience and sensitivity patterns, immune competence of the patient and disease severity. Combination therapy with an aminoglycoside and a beta-lactam has long been the cornerstone of therapy, and clinical success has been correlated with peak serum bactericidal levels of 1:8 in non-granulocytopenic patients and peak gentamicin and tobramycin levels greater than 8 micrograms/ml. The introduction of new broad-spectrum antibiotics, such as monobactams, third-generation cephalosporins and imipenem, has introduced the possibility of monotherapy for the treatment of nosocomial pneumonia. In general, monotherapy has proven to be a useful alternative to combination therapy, with success rates ranging from 77 to 96%. Development of resistance during therapy, particularly by Pseudomonas, Enterobacter and...Continue Reading

References

Mar 1, 1977·The American Journal of the Medical Sciences·J KlasterskyJ M Prevost
Jul 25, 1988·The American Journal of Medicine·R J MangiV T Andriole
Jan 1, 1988·The American Journal of Medicine·R J MangiV T Andriole
May 1, 1986·The American Journal of the Medical Sciences·G B Toews
May 1, 1986·The Journal of Antimicrobial Chemotherapy·C D SchwigonA Maslak
Jun 7, 1985·The American Journal of Medicine·R A SalataR J Duma
Nov 1, 1985·Reviews of Infectious Diseases·M E Levison, D Kaye
Dec 1, 1973·Antimicrobial Agents and Chemotherapy·L S Young, W L Hewitt
Jul 1, 1984·The Journal of Antimicrobial Chemotherapy·D P ReitbergJ J Schentag
Dec 21, 1984·The American Journal of Medicine·J J SchentagT J Cumbo
Jul 1, 1983·The Journal of Antimicrobial Chemotherapy·P FrancioliF A Waldvogel
May 15, 1984·The American Journal of Medicine·L S Young
Oct 1, 1984·The American Journal of Medicine·R D MooreP S Lietman
Jan 1, 1983·The American Review of Respiratory Disease·C R BodemE D Everett
Jan 1, 1981·Reviews of Infectious Diseases·J E Pennington
Feb 1, 1982·Clinical Endocrinology·G M BellA Doig

❮ Previous
Next ❯

Citations

Jan 1, 1992·Intensive Care Medicine·K E UnertlK Peter
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J H Wagenvoort
Jul 1, 1992·Diagnostic Microbiology and Infectious Disease·R J MangiV T Andriole
Nov 1, 1993·International Journal of Antimicrobial Agents·H Giamarellou
May 10, 2000·American Journal of Surgery·T C Fabian
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John H Powers
Feb 22, 2003·Surgical Infections·D E Fry
Aug 1, 1995·Chest·E Bergogne-Bérézin
Sep 1, 1992·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·C J Schleupner, D K Cobb
Jan 8, 2014·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Feb 1, 1996·Critical Care Medicine·T Ben-MenachemR S Bresalier
Sep 1, 1992·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·R L Thompson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.